Summary of Key Points Core Viewpoint - The company reported a shareholder loss of approximately $2.215 million for the six months ending June 30, 2025, compared to a loss of about $2.621 million in the same period last year [1] Group 1: Financial Performance - The company's shareholder loss decreased from $2.621 million to $2.215 million year-on-year [1] Group 2: Product Development - The main goal of Jiangsu Wanbang Pharmaceutical is to obtain market approval for Senstend™ in China by the end of 2025, with expectations for commercial launch in the first quarter of 2026 [1] - If the National Medical Products Administration grants an import license for Senstend™, Jiangsu Wanbang Pharmaceutical will need to pay the group $5 million (before Chinese withholding tax) [1] - After the first commercial sale of Senstend™ in China, Jiangsu Wanbang Pharmaceutical will owe the group an additional $2 million (before Chinese withholding tax) [1] Group 3: Clinical Research - The company has evaluated proposals from two well-known clinical research institutions regarding the Phase III clinical study of Fortacin™ in the United States and is in discussions with several pharmaceutical companies about licensing Fortacin™ in the U.S. market [1]

Core Viewpoint - The company reported significant revenue growth and a reduction in net loss for the six months ending June 30, 2025, indicating improved financial performance [1] Financial Performance - The group's revenue reached 237 million USD, representing a year-on-year increase of 92.68% [1] - The net loss narrowed to 2.215 million USD, a decrease of 15.49% compared to the previous year [1] - Earnings per share showed a loss of 0.961 cents [1]

Core Viewpoint - Lijinjing Pacific (00575) reported a significant increase in revenue and a reduction in net loss for the six months ending June 30, 2025, indicating improved financial performance [1] Financial Performance - The group's revenue reached $237,000, representing a year-on-year growth of 92.68% [1] - The net loss narrowed to $2.215 million, a decrease of 15.49% compared to the previous year [1] - Earnings per share showed a loss of 0.961 cents [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：���） 截至二零二五年六月三十日止六個月之 未經審核中期業績 業績概覽 截至二零二五年六月三十日止六個月之財務業績概要及其他重要事件包括： – 1 – • 本公司股東應佔虧損減少約2,220,000美元，主要是由於本集團的營運及研 發開支約2,250,000美元。 • Senstend™於中國的進展方面，江蘇萬邦醫藥的主要目標仍為於二零二五年 底前獲得入市批准，並預計於二零二六年第一季度開始首次商業化上市。倘 國家藥品監督管理局授予Senstend™進口許可證，江蘇萬邦醫藥將須向本集 團支付5,000,000美元（扣除中國預扣稅前）。此外，Senstend™於中國進行首 次商業銷售後，江蘇萬邦醫藥將須向本集團支付2,000,000美元（扣除中國預 扣稅前）。 • Fortacin™於美國的進展方面，本公司已評估兩家知名臨床研究機構（「臨床 研究機構」）關於 ...

Group 1 - The company, Lijing Pacific (00575.HK), announced that it will hold a board meeting on August 27, 2025, to approve the interim results for the six months ending June 30, 2025, and to consider the payment of an interim dividend, if any [1]

董事會會議日期 勵晶太平洋集團有限公司(「本公司」)董事會(「董事會」)謹此宣佈本公司將於 二零二五年八月二十七日(星期三)舉行董事會會議，藉以(其中包括)批准本公司及 其附屬公司截至二零二五年六月三十日止六個月之中期業績及其發佈，以及考慮 派付中期股息 (如有)。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 執行董事： Jamie Gibson （行政總裁） 非執行董事： James Mellon （主席） Jayne Sutcliffe 獨立非執行董事： Mark Searle 陳弘俊 Ihsan Al Chalabi 承董事會命 勵晶太平洋集團有限公司 執行董事 Jamie Gibson 香港，二零二五年八月十五日 於本公佈日期，董事會包括六名董事： ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勵晶太平洋集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 第 1 頁 共 11 頁 v 1.1.1 每股面值 0.001 美元之未分類股份，可發行為普通股或每股面值 0.001 美元之無投票權可換股遞延股份 FF301 第 2 頁 共 11 頁 v 1.1.1 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 ...

Group 1: Company Updates - Licheng Pacific (00575) announced that its strategic partner, Jiangsu Wanbang Biopharmaceutical Group, is advancing the new drug application for Senstend with the National Medical Products Administration of China [1] - Jiangsu Wanbang has received the first round of inquiries regarding the new drug application and has submitted a comprehensive response [1] - To support the new drug application, Jiangsu Wanbang submitted 900 commercial samples of Senstend produced by its manufacturing partners [1] - Jiangsu Wanbang remains optimistic about obtaining approval for the new drug application by the end of 2025 and plans to commercialize it in the first quarter of 2026 [1] Group 2: Deep Longevity Developments - Deep Longevity, Inc. has made significant progress in acquiring new clients, including Humansa Health in Hong Kong and Holistica World in India [2] - There has been an increase in the usage of Deep Longevity's aging clock among clients compared to the same period last year, indicating the growing value of the technology [2] - The company aims to establish new partnerships with B2C longevity applications, platforms, startups, and diagnostic companies [2] - Deep Longevity is focused on launching its aging clock in the U.S. market and has appointed a U.S. president to lead market expansion efforts [2] - The longevity and wellness market is estimated to be worth over $6.3 trillion in 2023, highlighting its potential for growth [2] Group 3: Product Innovations - Deep Longevity is actively engaging with longevity clinics and companies in Brazil, Germany, and Southeast Asia regarding the use of its aging clock [3] - The company has updated its biometric age feature, which now includes 17 blood biomarkers and 4 biological measurements, providing clients with additional metrics [3] - Deep Longevity is continuously updating its large language model to offer more accurate BloodAge and MindAge reports [3] - The company is researching the addition of a new clock focused on facial age or facial index score to its product line, along with other health, beauty, and wellness-focused clocks [3]

Summary of Key Points Core Viewpoint - As of April 30, a total of 43 stocks reached their 52-week highs, with notable performers including 廸生创建 (00113), 励晶太平洋 (00575), and 东方企控集团 (00018) achieving high rates of 17.01%, 13.73%, and 12.79% respectively [1]. 52-Week Highs - 廸生创建 (00113) closed at 6.840 with a peak of 6.880, marking a 17.01% increase [1]. - 励晶太平洋 (00575) reached a closing price of 0.970 and a high of 1.160, reflecting a 13.73% rise [1]. - 东方企控集团 (00018) had a closing price of 0.385 and a maximum of 0.485, showing a 12.79% increase [1]. - Other notable stocks include 茂盛控股 (00022) at 10.53%, and ＴＣＬ电子 (01070) at 8.70% [1]. 52-Week Lows - 中国疏浚环保 (00871) recorded a significant drop, closing at 0.098 with a low of 0.050, resulting in a -26.47% decline [2]. - 瑞和数智 (03680) fell to 0.330 with a low of 0.325, indicating a -12.16% change [2]. - 济丰包装 (01820) closed at 4.000, reaching a low of 3.500, which is a -12.06% decrease [2]. - Other companies experiencing declines include 中国卫生集团 (00673) at -8.97% and 亚太金融投资 (08193) at -6.56% [2].

Financial Performance - The Company reported a reduced loss attributable to shareholders of approximately US$4.48 million, primarily due to operating and R&D expenses of approximately US$4.99 million[2]. - The Group recorded a reduced loss attributable to shareholders of approximately US$4.48 million in 2024, down from US$25.05 million in 2023[15][34]. - Total revenue for 2024 was US$656,000, compared to a loss of US$539,000 in 2023, indicating a significant improvement[34]. - The operating loss after impairment losses and provisions for 2024 was US$4.34 million, a decrease from US$30.38 million in 2023[34]. - Revenue for the year ended December 31, 2024, increased to US$0.72 million, a 148.28% increase from US$0.29 million in 2023[191]. - Other income rose to US$0.08 million, reflecting a 166.67% increase from US$0.03 million in the previous year[191]. - Total loss attributable to shareholders decreased to US$4.48 million for the year ended December 31, 2024, an 82.12% reduction from US$25.05 million in 2023[191]. - Capital deficiency increased to approximately US$5.90 million as of December 31, 2024, up from approximately US$1.55 million as of December 31, 2023[194]. - The Group recorded no amortization of intangible assets for the year ended December 31, 2024, compared to US$22.18 million in 2023[198]. - The Group's income tax credit for the year ended December 31, 2024, was approximately US$26,000, a 99.45% decrease from US$5.42 million in 2023[198]. Product Development and Market Strategy - Wanbang Biopharmaceutical submitted the NDA to NMPA at the end of 2024, with approval expected within 12 months, and upon approval, the Group expects to receive US$5 million and an additional US$2 million upon first commercial sale of Senstend™ in China[2][7]. - The manufacturing and supply agreement was signed between Wanbang Biopharmaceutical, Genetic S.p.A., and Plethora Solutions Limited for the production of Senstend™ for the PRC market[2]. - The rights to Fortacin™ were out-licensed to Kobayashi Pharmaceutical Co., Ltd. for the Japanese market[2][7]. - The Company has completed the evaluation of two proposals for Phase 3 clinical studies of Fortacin™ in the US[2]. - The potential market for Senstend™ in China is approximately 9 million patients in its first year, growing to over 170 million patients by its tenth year[8]. - The Company is focused on the successful commercialization of Fortacin™/Senstend™ in key markets including China, the US, and Japan[4][5]. - The Company aims to commercialize its deep learning aging clock technology and partner with clinics and insurance companies[4][5]. - Deep Longevity is integrating its AI-led deep learning technology to build and commercialize various aging clocks[6]. - The Group aims to improve its financial performance and reduce losses in the upcoming fiscal year, as indicated by the significant decrease in losses reported[189]. Financial Position and Assets - Total assets decreased from US$80,310,000 in 2020 to US$610,000 in 2024, representing a decline of approximately 99.24%[37]. - Current liabilities increased significantly from US$9,105,000 in 2020 to US$5,649,000 in 2024, indicating a rise of about 62.5%[37]. - The Group's net liabilities reached US$5,901,000 in 2024, compared to net assets of US$50,305,000 in 2020, marking a substantial shift in financial position[37]. - The Group's current assets dropped from US$12,790,000 in 2021 to US$601,000 in 2024, a decrease of approximately 95.3%[37]. - The Group's intangible assets were fully impaired, decreasing from US$72,418,000 in 2020 to zero in 2024[37]. Corporate Governance and Compliance - The Group has complied with relevant laws and regulations that significantly impact its operations, ensuring adherence to applicable standards[42]. - The Group's financial risk management objectives and policies are detailed in the consolidated financial statements, indicating a structured approach to managing financial uncertainties[38]. - The company has applied all principles of the Corporate Governance Code and complied with applicable provisions during the year ended December 31, 2024[100]. - All directors have confirmed compliance with the Securities Dealing Code and the Model Code during the year ended December 31, 2024[99]. - The company has a strong governance structure with experienced professionals in key management positions, including a Chartered Secretary and a Chartered Governance Professional[188]. Share Options and Capital Structure - As of December 31, 2024, the total issued ordinary share capital consisted of 228,438,619 shares, unchanged from the previous year[55]. - The Share Option Scheme (2016) allows for 2,456,532 options available for grant as of December 31, 2024[64]. - No options were granted or exercised during the year ended December 31, 2024[65]. - The total number of options vested/unvested as of December 31, 2024, was 6,229,723[68]. - The company has not experienced any lapsing or cancellation of options during the year ended December 31, 2024[87]. - As of December 31, 2024, the company's distributable reserves amounted to approximately US$294 million, unchanged from 2023[88]. Leadership and Management - Jamie Alexander Gibson has been the CEO since May 2002, focusing on corporate finance and emerging market investment products[172]. - Jayne Allison Sutcliffe co-founded the Group in 1990 and has extensive experience in fund management, previously serving as Group Chief Executive of Charlemagne Capital Limited[175]. - Stawell Mark Searle has over 30 years of experience in investment management and has been an Independent Non-Executive Director since October 2001[175]. - Adrian Alan Chan has over 25 years of experience in accounting and financial management, serving as CFO for multiple companies including Enviro Energy International Holdings Limited[176][179]. - The management team includes experienced professionals such as Paul Eric Jones, who has over 30 years in the energy industry and corporate finance, and Michael Grant Wyllie, who has over 30 years in the pharmaceutical industry[185]. - The leadership team includes directors with diverse backgrounds in finance, law, and investment management, enhancing strategic decision-making[176][179]. Auditor and Financial Reporting - The Company has appointed RSM Hong Kong as the new auditor effective from June 21, 2023, following the resignation of BDO Limited[158]. - The company announced the resignation of RSM as the external auditor effective from July 16, 2024, due to a disagreement on the audit fee for the financial year ending December 31, 2024[162]. - Baker Tilly Hong Kong Limited was appointed as the new auditor effective from July 16, 2024, to fill the vacancy left by RSM, with a term until the next annual general meeting tentatively scheduled for June 2025[163]. - The consolidated financial statements for the year ended December 31, 2024, have been audited by Baker Tilly, which has expressed its willingness to continue in office and will seek re-appointment at the 2025 AGM[164]. - The Audit Committee reviewed RSM's audit fee proposal and deemed it inappropriate considering the current operational scale of the group and prevailing market rates[162].